Results 201 to 210 of about 53,280 (246)

6-mercaptopurine and tofacitinib alter microbial protein expression but not composition in fecal microbiota incubations from Crohn's disease patients. [PDF]

BMC Biol
Becker HEF, Mohren R, Le NG, Derijks LJJ, Jonkers DMAE, Penders J.   +5 more
europepmc   +1 more source

Real-world experience with Janus kinase inhibitors in rheumatoid and psoriatic arthritis: retention and discontinuation factors in a UK six-centre cohort. [PDF]

Rheumatol Adv Pract
Nathan J, Farisogullari B, Jones N, Ayoub M, Brown J, Levy S, Brader J, Ersoy A, Israni B, Lloyd M, Latheef A, Hill D, Taylor A, Arachchige D, Chitsu H, Linklater H, Lather K, Gompels L, Elfar E, Malaiya R, Machado PM, Kiely PDW.   +21 more
europepmc   +1 more source

A Case Series of Tofacitinib Treatment for Chronic Spontaneous Urticaria with Inadequate Response to Omalizumab. [PDF]

Clin Cosmet Investig Dermatol
Zhang X, Zhu M, Ye Y.
europepmc   +1 more source

Efficacy and Safety of Tofacitinib and Adalimumab in Rheumatoid Arthritis by Body Mass Index-Normalized Methotrexate Dose: A Post Hoc Analysis. [PDF]

Rheumatol Ther
Takeuchi T, Tanaka Y, Yamanaka H, Yamaoka K, Sugiyama N, Iikuni N, Toyoizumi S, Kwok K, Tsai WC, Mysler E, Moots RJ, Smolen JS, Fleischmann R.   +12 more
europepmc   +1 more source

From apremilast to JAK inhibitors-salvage treatment strategies for refractory palmoplantar pustulosis: case series. [PDF]

Front Med (Lausanne)
Pan Y, Jin D, Meng F, Zhang H, Tang J, Guo C, Li C, Ma J.   +7 more
europepmc   +1 more source

Multi-omics identification of immune-related biomarkers predicting tofacitinib response in rheumatoid arthritis. [PDF]

Front Immunol
Lu F, Shao Y, Chen Q, Liu Q, Liu H, Liu Z, Li Y.   +6 more
europepmc   +1 more source

Safety and efficacy of different JAK inhibitors in the treatment of inflammatory bowel disease: a network meta-analysis. [PDF]

Front Pharmacol
Wu H, Zhou Y, Chen X, Wang L, Guo Y, Du X, Miao X.   +6 more
europepmc   +1 more source

Targeting pathogenic Th17.1 cells via JAK-STAT3 pathway: A novel approach with tofacitinib for refractory myasthenia gravis. [PDF]

Neurotherapeutics
Zhao R, Yan C, Zhong H, Huan X, Jin L, He D, Xi J, Li Y, Xiao B, Luo F, Zhao C, Song J, Luo S.   +12 more
europepmc   +1 more source

Oral JAK Inhibitors as a Promising Therapeutic Strategy for Refractory Rosacea: A Systematic Review and Meta-Analysis. [PDF]

J Cosmet Dermatol
Peng Y, Sun M, Chen J, Huang X, Zhang F.
europepmc   +1 more source

Real-World Comparative Efficacy and Safety of Upadacitinib, Tofacitinib, and Filgotinib in Patients With Ulcerative Colitis. [PDF]

Cureus
Ahmad F, Hussain T, Gunaratne CH, Collum J, Ghaffar A, Gharbia K.   +5 more
europepmc   +1 more source